These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9359933)

  • 1. Opinion of the EMEA on the potential risk associated with medicinal products in relation to bovine spongiform encephalopathy (BSE) (16 April 1996) and report from the Committee for Proprietary Medicinal Products (CPMP) on the 'Note for Guidance on minimizing the risk of transmitting animal spongiform encephalopathies via medicinal products' (15 April 1997).
    Adverse Drug React Toxicol Rev; 1997 Jun; 16(2):113-21. PubMed ID: 9359933
    [No Abstract]   [Full Text] [Related]  

  • 2. Note for guidance. Guidelines for minimizing the risk of transmitting agents causing spongiform encephalopathy via medicinal products. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1992 Jun; 20(2):155-8. PubMed ID: 1389111
    [No Abstract]   [Full Text] [Related]  

  • 3. BSE--a risk for man through pharmaceutical products? Position and politics of the German pharmaceutical industry.
    Danner K
    Dev Biol Stand; 1993; 80():199-205. PubMed ID: 8270110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
    Kozak RW; Golker CF; Stadler P
    Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Viral safety: European and French directives].
    Rossi F; Legras JF
    Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S55-61. PubMed ID: 10896992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Transmissible spongiform encephalopathies in animals].
    Fatzer R; Vandevelde M
    Wien Med Wochenschr; 1998; 148(4):78-85. PubMed ID: 9611347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bovine sera used in the manufacture of biologicals: current concerns and policies of the U.S. Food and Drug Administration regarding the transmissible spongiform encephalopathies.
    Asher DM
    Dev Biol Stand; 1999; 99():41-4. PubMed ID: 10404874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gelatine production, the six steps to maximum safety.
    Schrieber R; Seybold U
    Dev Biol Stand; 1993; 80():195-8. PubMed ID: 8270109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trials of protecting Poland from acquiring bovine spongiform encephalopathy.
    Kita J; MacioĊ‚ek H
    Arch Immunol Ther Exp (Warsz); 1998; 46(2):65-8. PubMed ID: 9613702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms of the prion gene promoter region that influence classical bovine spongiform encephalopathy susceptibility are not applicable to other transmissible spongiform encephalopathies in cattle.
    Brunelle BW; Hamir AN; Baron T; Biacabe AG; Richt JA; Kunkle RA; Cutlip RC; Miller JM; Nicholson EM
    J Anim Sci; 2007 Dec; 85(12):3142-7. PubMed ID: 17709775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The welfare problems associated with using transgenic mice to bioassay for bovine spongiform encephalopathy.
    Jenkins ES; Combes RD
    Anim Welf; 1999; 8(4):421-31. PubMed ID: 11933934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of BSE risk assessments. Introduction.
    de Koeijer A; Havelaar A
    Risk Anal; 2007 Oct; 27(5):1091-3. PubMed ID: 18076482
    [No Abstract]   [Full Text] [Related]  

  • 13. [Bovine spongiform encephalopathy and natural scrapie].
    Fontaine JJ
    C R Seances Soc Biol Fil; 1997; 191(5-6):731-53. PubMed ID: 9587482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The research advance of analytical methodology for detecting bovine spongiform encephalopathy].
    Wei C; Liu G; Ma G; Tian X; Jin P; Peng C
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2005 Feb; 22(1):211-3. PubMed ID: 15762152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Australian response to BSE.
    Goldwater PN
    Aust Dent J; 2000 Dec; 45(4):290-1. PubMed ID: 11225536
    [No Abstract]   [Full Text] [Related]  

  • 16. Analysis of risk to biomedical products developed from animal sources (with special emphasis on the spongiform encephalopathy agents, scrapie and BSE).
    Rohwer RG
    Dev Biol Stand; 1996; 88():247-56. PubMed ID: 9119146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bovine spongiform encephalopathy in Europe. Present and future].
    Savey M; Belli P; Coudert M
    Vet Res; 1993; 24(2):213-25. PubMed ID: 8343806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of substances of animal origin in pharmaceutics and compliance with the TSE-risk guideline -- a market survey.
    Berger CN; Le Donne P; Windemann H
    Biologicals; 2005 Mar; 33(1):1-7. PubMed ID: 15713551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of milk and milk derivatives in relation to BSE: the lactoferrin example.
    Vetrugno V
    Biometals; 2004 Jun; 17(3):353-6. PubMed ID: 15222490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostics for TSE agents.
    Raeber AJ; Oesch B
    Dev Biol (Basel); 2006; 123():313-23; discussion 349-54. PubMed ID: 16566455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.